Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8001 + BAT1306 in HER2-positive advanced solid tumors
CTR20181946Phase 2Terminated
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Apr 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BAT8001, bat1306 in HER2-overexpressing solid tumor, sponsored by Bio-Thera Solutions, Ltd.. Started Apr 2019; status: terminated.
02
Drugs
BAT8001bat1306
03
Conditions
HER2-overexpressing solid tumor
Beyond the preview
Go deeper on CTR20181946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181946.